KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has disclosed Cash & Equivalents for 11 consecutive years, with $347.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 16.53% to $347.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $347.6 million through Dec 2025, up 16.53% year-over-year, with the annual reading at $347.6 million for FY2025, 16.53% up from the prior year.
  • Cash & Equivalents hit $347.6 million in Q4 2025 for CRISPR Therapeutics AG, up from $286.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.6 billion in Q2 2021 to a low of $193.6 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $554.0 million across 5 years, with a median of $464.6 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 77.04% in 2022 and later soared 105.4% in 2024.
  • Year by year, Cash & Equivalents stood at $923.0 million in 2021, then tumbled by 77.04% to $211.9 million in 2022, then surged by 83.82% to $389.5 million in 2023, then fell by 23.41% to $298.3 million in 2024, then rose by 16.53% to $347.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for CRSP at $347.6 million in Q4 2025, $286.5 million in Q3 2025, and $193.6 million in Q2 2025.